Cullinan Oncology Inc   (CGEM)
Other Ticker:  

Business expenses have been increasing at the company in the financial time-frame ending September 30 2022

company delivered third quarter of 2022 operating deficit of $-29.766 millions

Published 2022-11-16T22:21:59+00:00
Goran Soko / CSIMarket.com Contributer

SOLAR_erde_By_Jjkujk_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons Following the leaders in the Renewable Energy Services & Equipment sector, a number of overlooked entities are reporting the earnings. Cullinan Oncology Inc revealed it has booked operating deficit of $-29.766 millions, for the third quarter of 2022.

The operating deficit has contracted from $-18.375 millions, from the third quarter of 2021. But more crucially, the analysts are ruminating, when the Cullinan Oncology Inc s' will start to show the revenue.

Not alarmingly the evolving firm reported a net loss of $-24.890 millions, which has extended from $-18.259 millions, in the comparable three months a year before.

Cullinan Oncology Inc is expected to report next financial earnings on March 16, 2023.

    Recently Reported Results